Xermelo
Xermelo Xermelo (generic: xeremonib) is a next‑generation epidermal growth factor receptor (EGFR) kinase inhibitor approved for advanced non‑small‑cell lung cancer (NSCLC) harboring the T790M resistance mutation following first‑ or second‑generation…